Dataset Information

Age-related changes in plasma biomarkers and their association with mortality in COVID-19.

ABSTRACT:

Background

Coronavirus disease 2019 (COVID-19)-induced mortality occurs predominantly in older patients. Several immunomodulating therapies seem less beneficial in these patients. The biological substrate behind these observations is unknown. The aim of this study was to obtain insight into the association between ageing, the host response and mortality in patients with COVID-19.

Methods

We determined 43 biomarkers reflective of alterations in four pathophysiological domains: endothelial cell and coagulation activation, inflammation and organ damage, and cytokine and chemokine release. We used mediation analysis to associate ageing-driven alterations in the host response with 30-day mortality. Biomarkers associated with both ageing and mortality were validated in an intensive care unit and external cohort.

Results

464 general ward patients with COVID-19 were stratified according to age decades. Increasing age was an independent risk factor for 30-day mortality. Ageing was associated with alterations in each of the host response domains, characterised by greater activation of the endothelium and coagulation system and stronger elevation of inflammation and organ damage markers, which was independent of an increase in age-related comorbidities. Soluble tumour necrosis factor receptor 1, soluble triggering receptor expressed on myeloid cells 1 and soluble thrombomodulin showed the strongest correlation with ageing and explained part of the ageing-driven increase in 30-day mortality (proportion mediated: 13.0%, 12.9% and 12.6%, respectively).

Conclusions

Ageing is associated with a strong and broad modification of the host response to COVID-19, and specific immune changes likely contribute to increased mortality in older patients. These results may provide insight into potential age-specific immunomodulatory targets in COVID-19.

SUBMITTER: Michels EHA

PROVIDER: S-EPMC10151455 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Age-related changes in plasma biomarkers and their association with mortality in COVID-19.

Michels Erik H A EHA Appelman Brent B de Brabander Justin J van Amstel Rombout B E RBE Chouchane Osoul O van Linge Christine C A CCA Schuurman Alex R AR Reijnders Tom D Y TDY Sulzer Titia A L TAL Klarenbeek Augustijn M AM Douma Renée A RA Bos Lieuwe D J LDJ Wiersinga W Joost WJ Peters-Sengers Hessel H van der Poll Tom T van Agtmael Michiel M Algera Anne Geke AG Appelman Brent B van Baarle Floor F Beudel Martijn M Bogaard Harm Jan HJ Bomers Marije M Bonta Peter P Bos Lieuwe L Botta Michela M de Brabander Justin J de Bree Godelieve G de Bruin Sanne S Bugiani Marianna M Bulle Esther E Buis David T P DTP Chouchane Osoul O Cloherty Alex A Dijkstra Mirjam M Dongelmans Dave A DA Dujardin Romein W G RWG Elbers Paul P Fleuren Lucas L Geerlings Suzanne S Geijtenbeek Theo T Girbes Armand A Goorhuis Bram B Grobusch Martin P MP Hagens Laura L Hamann Jorg J Harris Vanessa V Hemke Robert R Hermans Sabine M SM Heunks Leo L Hollmann Markus M Horn Janneke J Hovius Joppe W JW de Jong Hanna K HK de Jong Menno D MD Koning Rutger R Lemkes Bregje B Lim Endry H T EHT van Mourik Niels N Nellen Jeaninne J Nossent Esther J EJ Olie Sabine S Paulus Frederique F Peters Edgar E Pina-Fuentes Dan A I DAI van der Poll Tom T Preckel Bennedikt B Prins Jan M JM Raasveld Jorinde J Reijnders Tom T de Rotte Maurits C F J MCFJ Schinkel Michiel M Schultz Marcus J MJ Schrauwen Femke A P FAP Schuurman Alex A Schuurmans Jaap J Sigaloff Kim K Slim Marleen A MA Smeele Patrick P Smit Marry M Stijnis Cornelis S CS Stilma Willemke W Teunissen Charlotte C Thoral Patrick P Tsonas Anissa M AM Tuinman Pieter R PR van der Valk Marc M Veelo Denise P DP Volleman Carolien C de Vries Heder H Vught Lonneke A LA van Vugt Michèle M Wouters Dorien D Zwinderman A H Koos AHK Brouwer Matthijs C MC Wiersinga W Joost WJ Vlaar Alexander P J APJ van de Beek Diederik D

The European respiratory journal 20230707 1

<h4>Background</h4>Coronavirus disease 2019 (COVID-19)-induced mortality occurs predominantly in older patients. Several immunomodulating therapies seem less beneficial in these patients. The biological substrate behind these observations is unknown. The aim of this study was to obtain insight into the association between ageing, the host response and mortality in patients with COVID-19.<h4>Methods</h4>We determined 43 biomarkers reflective of alterations in four pathophysiological domains: endo ...[more]

PMID: 37080568

Similar Datasets

Project description:ObjectiveTo evaluate the association between common biomarkers, death and intensive care unit (ICU) admission in patients with COVID-19.DesignRetrospective cohort study. From electronic national registry data, we used Cox analysis and bootstrapping to evaluate associations between baseline levels of biomarkers and standardised absolute risks of death/ICU admission, adjusted for age and gender.SettingAll hospitals in Denmark.Participants1310 patients aged ≥18 years admitted to hospital with COVID-19 from 27th of February to 1st of May 2020, with available biochemistry data.Main outcome measuresA composite of death/ICU admission occurring within 30 days.ResultsOf the 1310 patients admitted to hospital (54.6% men; median age 73.6 years), 352 (26.9%) experienced the composite endpoint and 263 (20.1%) died. For the composite endpoint, the absolute risks for moderately and severely elevated C reactive protein (CRP) were significantly higher, 21.5% and 39.2%, respectively, compared with 5.0% for those with normal CRP. Moderately and severely elevated leucocytes were significantly higher, 34.5% and 46.6% risk, respectively, compared with 23.2% for those with normal leucocytes. Moderately and severely decreased estimated glomerular filtration rates (eGFR) were significantly higher, 41.5% and 45.9% risk, respectively, compared with 30.4% for those with normal/mildly decreased eGFR. Normal and elevated ureas were significantly higher, 22.3% and 40.6% risk, respectively, compared with 7.3% for those with low urea. Elevated D-dimer was significantly higher, 31.8% risk, compared with 17.5% for those with normal D-dimer. Moderately and severely elevated troponins were significantly higher, 27.7% and 57.3% risk, respectively, compared with 9.4% for those with normal troponin. Elevated procalcitonin was significantly higher, 52.1% risk, compared with 28.0% for those with normal procalcitonin.ConclusionIn this nationwide study of patients admitted with COVID-19, elevated levels of CRP, leucocytes, procalcitonin, urea, troponins and D-dimer, and low levels of eGFR were associated with higher standardised absolute risk of death/ICU admission within 30 days.

Project description:BackgroundThe relationship between vitamin D status and COVID-19-related clinical outcomes is controversial. Prior studies have been conducted in smaller, single-site, or homogeneous populations limiting adjustments for social determinants of health (race/ethnicity and poverty) common to both vitamin D deficiency and COVID-19 outcomes.ObjectiveTo evaluate the dose-response relationship between continuous 25(OH)D and risk for COVID-19-related hospitalization and mortality after adjusting for covariates associated with both vitamin D deficiency and COVID-19 outcomes.DesignRetrospective cohort study.PatientsVeteran patients receiving care in US Department of Veteran Affairs (VA) health care facilities with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test and a blood 25(OH)D test between February 20, 2020, and November 8, 2020, followed for up to 60 days.Main measuresExposure was blood 25(OH)D concentration ascertained closest to and within 15 to 90 days preceding an index positive SARS-CoV-2 test. Co-primary study outcomes were COVID-19-related inpatient hospitalization requiring airborne, droplet, contact, or other isolation and mortality ascertained within 60 days of an index positive SARS-CoV-2 test.Key resultsOf 4,599 veterans with a positive SARS-CoV-2 test, vitamin D deficiency (< 20 ng/mL) was identified in 665 (14.5%); 964 (21.0%) were hospitalized; and 340 (7.4%) died. After adjusting for all covariates, including race/ethnicity and poverty, there was a significant independent inverse dose-response relationship between increasing continuous 25(OH)D concentrations (from 15 to 60 ng/mL) and decreasing probability of COVID-19-related hospitalization (from 24.1 to 18.7%, p=0.009) and mortality (from 10.4 to 5.7%, p=0.001). In modeling 25(OH)D as a log-transformed continuous variable, the greatest risk for hospitalization and death was observed at lower 25(OH)D concentrations.ConclusionsContinuous blood 25(OH)D concentrations are independently associated with COVID-19-related hospitalization and mortality in an inverse dose-response relationship in this large racially and ethnically diverse cohort of VA patients. Randomized controlled trials are needed to evaluate the impact of vitamin D supplementation on COVID-19-related outcomes.

Project description:Rationale: Lymphopenia in coronavirus disease (COVID-19) is associated with increased mortality. Objectives: To explore the association between lymphopenia, host response aberrations, and mortality in patients with lymphopenic COVID-19. Methods: We determined 43 plasma biomarkers reflective of four pathophysiological domains: endothelial cell and coagulation activation, inflammation and organ damage, cytokine release, and chemokine release. We explored if decreased concentrations of lymphocyte-derived proteins in patients with lymphopenia were associated with an increase in mortality. We sought to identify host response phenotypes in patients with lymphopenia by cluster analysis of plasma biomarkers. Measurements and Main Results: A total of 439 general ward patients with COVID-19 were stratified by baseline lymphocyte counts: normal (>1.0 × 109/L; n = 167), mild lymphopenia (>0.5 to ⩽1.0 × 109/L; n = 194), and severe lymphopenia (⩽0.5 × 109/L; n = 78). Lymphopenia was associated with alterations in each host response domain. Lymphopenia was associated with increased mortality. Moreover, in patients with lymphopenia (n = 272), decreased concentrations of several lymphocyte-derived proteins (e.g., CCL5, IL-4, IL-13, IL-17A) were associated with an increase in mortality (at P < 0.01 or stronger significance levels). A cluster analysis revealed three host response phenotypes in patients with lymphopenia: "hyporesponsive" (23.2%), "hypercytokinemic" (36.4%), and "inflammatory-injurious" (40.4%), with substantially differing mortality rates of 9.5%, 5.1%, and 26.4%, respectively. A 10-biomarker model accurately predicted these host response phenotypes in an external cohort with similar mortality distribution. The inflammatory-injurious phenotype showed a remarkable combination of relatively high inflammation and organ damage markers with high antiinflammatory cytokine levels yet low proinflammatory cytokine levels. Conclusions: Lymphopenia in COVID-19 signifies a heterogenous group of patients with distinct host response features. Specific host responses contribute to lymphopenia-associated mortality in COVID-19, including reduced CCL5 levels.

Dataset Information

Age-related changes in plasma biomarkers and their association with mortality in COVID-19.

Background

Methods

Results

Conclusions

Publications

Age-related changes in plasma biomarkers and their association with mortality in COVID-19.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets